undamentalytics Newsletter
Sign in

Aethlon Medical Inc (AEMD) stock

Add to watchlist

Add holding +

NASDAQ: AEMD Nasdaq Health Care Equipment Next results ~November 11, 2026

Aethlon Medical Inc is a US-listed company in the health care equipment industry. Its financial year ends in March.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Current signal Revenue growth accelerating: TTM revenue growth rose to 95.2% (+191.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 95.2% over the last 12 months.
  • Growth speeding up. The growth rate is 191.1 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 1470.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -2072.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -1993.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 183.2% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 28.2% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 388% and a beta of 4.3 against the S&P 500.

Latest results: FY2023 Q4

Filed June 27, 2024
Earnings per share
-$4.02 against an average estimate of -$4.05: beat by 0.7%
Revenue
$1m, up 4278.2% on a year earlier
Share reaction
-6.9% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$2.90

Aethlon Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.8%
  • 1 week+2.7%
  • 1 month-18.0%
  • This year-61.8%
  • 1 year-79.9%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 13, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Governance
  2. Leadership
  3. Agreement
  4. Leadership
  5. Announcement
  6. Results
  7. Governance
  8. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aethlon Medical Inc valuation models and calculator

No model value for Aethlon Medical Inc at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

12 /100

Weak moat

How hard Aethlon Medical's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -89.6% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -1197.2%; its worst year was -3542.5%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -1452.6% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 8039.3% over five years; stock-based pay has been a median 129.8% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026. Analysts expect revenue of $0 and EPS of −$2.90 (range −$3.64 to −$2.17) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$5.74 +89% — 0%
Next −$0.57 +90% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +17.0% on 90 days ago. In the last 30 days, 1 analyst raised Aethlon Medical Inc's forecast and 0 cut it.

Consensus EPS forecast Aethlon Medical Inc, last 90 days
−$20.00 −$15.00 −$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.90 Current fiscal year, 60 days ago: −$16.15 Current fiscal year, 30 days ago: −$16.15 Current fiscal year, 7 days ago: −$16.15 Current fiscal year, Now: −$5.74 −$5.74 Next fiscal year, 90 days ago: −$2.50 Next fiscal year, 60 days ago: −$2.50 Next fiscal year, 30 days ago: −$2.50 Next fiscal year, 7 days ago: −$2.50 Next fiscal year, Now: −$0.57 −$0.57

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.90−$2.50
60 days ago −$16.15−$2.50
30 days ago −$16.15−$2.50
7 days ago −$16.15−$2.50
Now −$5.74−$0.57

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$4.05 −$4.02 +0.7%
Dec 2025 −$10.05 −$12.25 −21.9%
Sept 2025 −$8.47 −$18.70 −120.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy00%
Hold2100%
Sell00%

Monthly trend

  1. Oct 202622
  2. Sep 202622

Counts of recommendations published by analysts covering Aethlon Medical Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.1%
of tradable shares
Days to cover
0.01
at average volume
Short interest, 1 month
−56%
to October 15, 2026
Held by institutions
7%
of shares
Held by insiders
3.1%
of shares
Employees
9
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
AEMD−85%−85%−22%−61%−96%−62%
Industry peers (median)−7%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
AEMD8%17%42%42%17%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
AEMD−88%−87%−80%−88%−97%−91%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 2, 2015 to September 16, 2026. Getting back needed a 172027872% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.43 – $24.75
From 52-week high
−78.6%
vs 50-day average
+17.0%
vs 200-day average
−31.6%
Volatility (1 year)
388%
Beta vs S&P 500
4.35

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±9.2%
After a week
2 up, 10 down
typical move ±15.7%
After a month
3 up, 9 down
typical move ±28.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −6.9% +0.5% −11.2% −49.3%
June 10, 2026 −2.1% +0.1% −1.5% −65.5%
February 12, 2026 −6.2% −1.5% −3.8% +1.0%
November 12, 2025 +9.2% −1.6% −13.1% −21.7%
August 13, 2025 −7.1% +0.4% −11.9% −38.9%
June 27, 2025 −38.1% +1.0% −39.7% −38.1%
February 12, 2025 −7.4% +0.7% −10.3% −45.6%
November 13, 2024 +2.6% −0.6% 0.0% −7.7%
August 14, 2024 −3.0% +2.0% +69.7% +15.2%
June 27, 2024 −15.3% −0.2% −23.7% −35.6%
February 14, 2024 −5.2% +1.6% −1.2% 0.0%
November 14, 2023 +7.9% +2.2% +1.8% +21.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Aethlon Medical Inc
$0 $500K $1M FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 Revenue (TTM), FY21 Q1: $620.2K Revenue (TTM), FY21 Q2: $620.2K Revenue (TTM), FY21 Q3: $831.6K Revenue (TTM), FY21 Q4: $659.1K Revenue (TTM), FY22 Q1: $791.1K Revenue (TTM), FY22 Q2: $923K Revenue (TTM), FY22 Q3: $315.3K Revenue (TTM), FY22 Q4: $294.2K Revenue (TTM), FY23 Q1: $162.2K Revenue (TTM), FY23 Q2: $30.2K Revenue (TTM), FY23 Q3: $13.1K Revenue (TTM), FY23 Q4: $574.2K $574.2K

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY21 Q1 $620.2K
FY21 Q2 $620.2K
FY21 Q3 $831.6K
FY21 Q4 $659.1K
FY22 Q1 $791.1K
FY22 Q2 $923K
FY22 Q3 $315.3K
FY22 Q4 $294.2K
FY23 Q1 $162.2K
FY23 Q2 $30.2K
FY23 Q3 $13.1K
FY23 Q4 $574.2K
Revenue growth, TTM YoY Aethlon Medical Inc
-200% 0% 200% 400% 600% FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 Revenue growth, TTM YoY, FY21 Q1: 463.8% Revenue growth, TTM YoY, FY21 Q2: 463.8% Revenue growth, TTM YoY, FY21 Q3: 58.9% Revenue growth, TTM YoY, FY21 Q4: 1.4% Revenue growth, TTM YoY, FY22 Q1: 27.6% Revenue growth, TTM YoY, FY22 Q2: 48.8% Revenue growth, TTM YoY, FY22 Q3: -62.1% Revenue growth, TTM YoY, FY22 Q4: -55.4% Revenue growth, TTM YoY, FY23 Q1: -79.5% Revenue growth, TTM YoY, FY23 Q2: -96.7% Revenue growth, TTM YoY, FY23 Q3: -95.8% Revenue growth, TTM YoY, FY23 Q4: 95.2% 95.2%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY21 Q1 463.8%
FY21 Q2 463.8%
FY21 Q3 58.9%
FY21 Q4 1.4%
FY22 Q1 27.6%
FY22 Q2 48.8%
FY22 Q3 -62.1%
FY22 Q4 -55.4%
FY23 Q1 -79.5%
FY23 Q2 -96.7%
FY23 Q3 -95.8%
FY23 Q4 95.2%
Operating margin (TTM) Aethlon Medical Inc
-150000% -100000% -50000% 0% FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 Operating margin (TTM), FY21 Q1: -931.0% Operating margin (TTM), FY21 Q2: -942.2% Operating margin (TTM), FY21 Q3: -891.2% Operating margin (TTM), FY21 Q4: -1197.2% Operating margin (TTM), FY22 Q1: -1084.5% Operating margin (TTM), FY22 Q2: -955.1% Operating margin (TTM), FY22 Q3: -2822.8% Operating margin (TTM), FY22 Q4: -3542.5% Operating margin (TTM), FY23 Q1: -6922.7% Operating margin (TTM), FY23 Q2: -42619.1% Operating margin (TTM), FY23 Q3: -100692.6% Operating margin (TTM), FY23 Q4: -2072.1% -2072.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY21 Q1 -931.0%
FY21 Q2 -942.2%
FY21 Q3 -891.2%
FY21 Q4 -1197.2%
FY22 Q1 -1084.5%
FY22 Q2 -955.1%
FY22 Q3 -2822.8%
FY22 Q4 -3542.5%
FY23 Q1 -6922.7%
FY23 Q2 -42619.1%
FY23 Q3 -100692.6%
FY23 Q4 -2072.1%
FCF margin (TTM) Aethlon Medical Inc
-100000% -50000% 0% FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 FCF margin (TTM), FY21 Q1: -841.8% FCF margin (TTM), FY21 Q2: -848.2% FCF margin (TTM), FY21 Q3: -746.1% FCF margin (TTM), FY21 Q4: -1035.5% FCF margin (TTM), FY22 Q1: -987.9% FCF margin (TTM), FY22 Q2: -921.0% FCF margin (TTM), FY22 Q3: -2870.1% FCF margin (TTM), FY22 Q4: -3439.0% FCF margin (TTM), FY23 Q1: -6643.8% FCF margin (TTM), FY23 Q2: -41263.4% FCF margin (TTM), FY23 Q3: -89979.5% FCF margin (TTM), FY23 Q4: -1993.6% -1993.6%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q1 -841.8%
FY21 Q2 -848.2%
FY21 Q3 -746.1%
FY21 Q4 -1035.5%
FY22 Q1 -987.9%
FY22 Q2 -921.0%
FY22 Q3 -2870.1%
FY22 Q4 -3439.0%
FY23 Q1 -6643.8%
FY23 Q2 -41263.4%
FY23 Q3 -89979.5%
FY23 Q4 -1993.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2012 Mar 2012 2013 Mar 2013 2014 Mar 2014 2015 Mar 2015 2016 Mar 2016 2017 Mar 2017 2018 Mar 2018 2019 Mar 2019 2020 Mar 2020 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024
Income
Revenue 1 1 2 1 1 0 0 0 1 1 0 1 0
EBITDA −3 −4 −3 −4 −4 −6 −5 −6 −6 −8 −10 −12 −12
Operating income −3 −4 −3 −4 −4 −6 −5 −6 −6 −8 −10 −12 −13
Net income −8 −5 −13 −7 −5 −7 −6 −6 −6 −8 −10 −12 −12
Diluted EPS −$4.00 −$1800.00 −$4128.00 −$1.22 −$0.66 −$0.94 −$120.00 −$410.40 −$149.60 −$52.00 −$0.71 −$46.88 −$38.87
Growth (year on year)
Revenue — −9.5% +32.0% −53.0% +16.3% −55.8% −61.8% +53.5% +183.2% +1.4% −55.4% +95.2% −100.0%
Margins
EBITDA margin −227.8% −289.8% −186.9% −518.8% −490.2% <−999% <−999% <−999% −908.0% <−999% <−999% <−999% —
Operating margin −229.1% −290.7% −188.2% −523.7% −494.6% <−999% <−999% <−999% −912.0% <−999% <−999% <−999% —
Net margin −596.6% −397.7% −822.6% −891.5% −549.6% <−999% <−999% <−999% −980.3% <−999% <−999% <−999% —
Free-cash-flow margin −135.6% −170.6% −137.6% −662.3% −489.4% −898.4% <−999% <−999% −822.7% <−999% <−999% <−999% —
Cash flow
Cash from operations −2 −2 −2 −5 −4 −4 −4 −4 −5 −7 −10 −11 −10
Capital spending 0 0 0 0 0 0 0 0 0 0 0 1 0
Free cash flow −2 −2 −2 −5 −4 −4 −4 −4 −5 −7 −10 −11 −10
Stock-based pay 1 1 1 0 0 2 1 1 1 1 1 1 1
Free cash flow after stock pay −3 −3 −3 −5 −5 −6 −5 −6 −6 −8 −11 −13 −12
Balance sheet
Cash — — — — — — — 4 10 10 17 15 5
Total debt 4 3 3 0 1 1 — 1 — 0 0 0 0
Net debt (negative = net cash) — — — — — — — −3 −10 −10 −17 −15 −5
Diluted shares — — — — 6m 6m 10m 15m — — — — —
Returned to shareholders
Buybacks — — — — 0 0 0 0 — — — — —
Total returned — — — — 0 0 0 0 — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated AEMD ITOC CODX QTEX PLSE NXL Median
Revenue, last 12 months $574245 $523031 $721387 $289000 $1m $217155 $95m
Revenue growth, last 12 months 95.2% 16.7% −28.1% — 100.0% 24.2% 9.3%
Revenue growth, 3-year average −4.1% — −53.8% — — −30.6% 13.0%
Revenue growth, latest quarter >999% — 2.0% — 100.0% −82.8% 10.5%
Gross margin — 62.6% 43.5% 0.7% 0.3% 86.2% 61.2%
Operating margin <−999% −991.7% <−999% <−999% <−999% <−999% −8.7%
Operating margin, 3-year average <−999% — <−999% — >999% <−999% −17.9%
Net margin <−999% −974.7% <−999% <−999% <−999% <−999% −12.1%
Cash from operations / revenue <−999% −617.8% <−999% <−999% <−999% <−999% −2.1%
Free-cash-flow margin <−999% −618.6% <−999% <−999% <−999% <−999% −4.0%
Free-cash-flow margin, 3-year average <−999% — <−999% — >999% <−999% −7.7%
Stock pay / revenue 183.2% 563.2% 169.9% >999% >999% >999% 6.3%
Change in share count 28.2% 26.1% 4.0% 60.0% 7.4% 52.1% 4.0%

Median of all 135 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • June 10, 2026
  • February 12, 2026
  • November 12, 2025
  • August 13, 2025
  • June 27, 2025

Recent SEC filings

Data status

When each part of this page on Aethlon Medical Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Aethlon Medical Inc in brief

What does Aethlon Medical Inc do?
Aethlon Medical Inc is a US-listed company in the health care equipment industry. Its financial year ends in March.
What is Aethlon Medical Inc's stock ticker?
Aethlon Medical Inc trades under the ticker AEMD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Aethlon Medical Inc's market cap?
On March 28, 2024, Aethlon Medical Inc's market capitalisation was about $211M and net debt of -$5.4M. Market figures come from third-party market data and may be delayed.
Who are Aethlon Medical Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Aethlon Medical Inc are Itonic Holdings Ltd, Co-diagnostics, Inc., Qtrex Quantum Ltd., Pulse Biosciences, Inc. and Nexalin Technology, Inc. The side-by-side comparison below sets their revenue, margins and growth against Aethlon Medical Inc's.
When is Aethlon Medical Inc's next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aethlon Medical Inc announces its own schedule.